Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Smith
Ian E
IE
The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. ian.smith@rmh.nhs.uk
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D004164:Diphosphonates / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077211:Zoledronic Acid; D000077289:Letrozole